Now Is the Time to Bet on Pot Stocks

Pot stocks like Hexo Corp (TSX:HEXO)(NYSE:HEXO) can make you rich, but you need to know how to invest.

Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Pot stocks were hammered in 2019. Nearly every company lost at least 50% of its value. Cannabis demand, on the other hand, continues to climb. This disconnect provides patient investors a clear path to profit.

As with any early-stage market, investors scrambled at the chance to inject pent-up capital into cannabis companies. In 2018, many pot stocks rose by more than 1,000%. By 2019, the hype bubble had popped, sending short-term investors to the sidelines.

Pot stocks were overvalued in 2018, but there’s an argument that the pendulum has swung too far the other way. It doesn’t take a mathematician to realize that many cannabis producers are trading at bargain valuations.

You’ll need to keep a long-term outlook, but now looks like the time to buy beaten-down pot stocks.

Understand what’s happening

Fortune magazine recently ran a story headlined: “Why investors suddenly turned on pot stocks.” The findings were clear.

“Supply and demand issues have wreaked havoc on that Holy Grail of pleasing Wall Street—earnings estimates,” the article claimed. “Despite the roll-out of legal marijuana in Canada, many companies struggled to gauge demand and product mix amid a lackluster number of retail stores in Canada, resulting in an oversupply of product for some. And in the U.S., where cannabis is still federally illegal, the regulatory climate and a vaping crisis last summer only exacerbated cash problems.”

Most analysts expect cannabis to be federally legalized in the U.S. by the end of the decade, while the vaping health crisis was a temporary headwind. Those two issues don’t present permanent challenges. There is one long-term hurdle that the story correctly identifies: oversupply.

Early last year, before the cannabis bear market picked up steam, I published a post titled: The #1 Cannabis Risk That No One Is Talking About.

“At the end of the day, cannabis companies are simply growing crops. The planting and harvesting cycle isn’t too different from corn, tomatoes, or soybean,” I wrote. “Today, it’s not very profitable to grow staples like tomatoes, beans, rice, or cabbage. In another decade, there’s a chance that growing cannabis isn’t wildly profitable either. That reality could crush nearly every cannabis stock. Commoditization could be a lot closer than you think,” I concluded.

By the summer, Tilray revealed that its pricing had fallen off a cliff. Other producers soon followed. And thus the industry-wide downturn began.

A limited-time opportunity

The long-term commodity risk is finally being appreciated by the market. Once high-flying stocks like Green Organic Dutchman Holdings Ltd now have to prove that ramping up pot production can actually result in real profits.

Green Organic was once a billion-dollar company. Today it’s worth just $150 million. Until it can prove that commoditization won’t kill its business, expect the stock to remain in the penalty box.

There are some stocks, however, that trade at depressed multiples but have reasonable plans to overcome long-term commoditization. Hexo Corp is a perfect example.

Hexo’s strategy involves partnering with existing brands like Molson Coors Beverage Co to launch products that consumers already trust. Coca-Cola Co can sell you five cents worth of commodities for a dollar. Hexo is betting it can do the same thing with branded pot.

Many pot stocks have gotten cheap for a reason. Others have been brought down by the industry-wide collapse. It can pay to “buy when there’s blood in the streets,” but just be sure that the stocks you own have strategic partners that can help them brand and differentiate their products.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »